

SEC14L2 RABBIT PAB

货号: S220888

产品全名: SEC14L2 兔多抗

基因符号: SPF; TAP; TAP1; C22orf6

UNIPROT ID: O76054 (Gene Accession - NP_001191133)

背景: This gene encodes a cytosolic protein which belongs to a family of lipid-binding proteins including Sec14p, alpha-tocopherol transfer protein, and cellular retinol-binding protein. The encoded protein stimulates squalene monooxygenase which is a downstream enzyme in the cholesterol biosynthetic pathway. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene.

抗原: Synthetic peptide of human SEC14L2

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 25-100;WB: 500-2000;ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 220888(SEC14L2 Antibody) at a dilution of 1/40(Cytoplasm).




In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 220888(Anti-SEC14L2 Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 220888(Anti-SEC14L2 Antibody) at a dilution of 1/40.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with synthetic peptide and then with D262176(Anti-SEC14L2 Antibody) at dilution 1/40.



Gel: 8%SDS-PAGE, Lysate: 40 µg;
Lane 1-3: Mouse liver tissue, PC3 cells, human fetal liver tissue;
Primary antibody: 220888(SEC14L2 Antibody) at dilution 1/400;
Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;
Exposure time: 2 minutes



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
